The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 1, 2006, Pages 70-81

  Hayeshi, Rose ^a   Masimirembwa, Collen ^b   Mukanganyama, Stanley ^a   Ungell, Anna Lena B ^c  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b African Institute of Biomedical Science and Technology   (Zimbabwe)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiparasitic drugs; Caco 2 cells; Drug interactions; Food interactions; Natural compounds; P glycoprotein; Taxol

Indexed keywords

AMODIAQUINE; ANTIPARASITIC AGENT; ARTEMISININ; ARTESUNATE; BENZBROMARONE; CHLOROQUINE; CYCLOGUANIL; DAPSONE; DEETHYLAMODIAQUINE; DIETHYLCARBAMAZINE; DIHYDROARTEMISININ; FLAVONE; GENISTEIN; GLYCOPROTEIN P INHIBITOR; INDOMETACIN; MELARSOPROL; METRIFONATE; NATURAL PRODUCT; PACLITAXEL; PRAZIQUANTEL; PRIMAQUINE; PROGUANIL; PYRANTEL; PYRIMETHAMINE; QUERCETIN; QUININE; SURAMIN; TIABENDAZOLE; TINIDAZOLE; UNINDEXED DRUG;

ABSORPTION; ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSPORT KINETICS;

ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIPARASITIC AGENTS; BIOLOGICAL PRODUCTS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; FLAVONOIDS; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PHENOLS; PLANTS; VERAPAMIL;

EID: 33748062666     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.05.009     Document Type: Article

References (55)

1. Abegaz B.M., and Kebede T. Geshoidin: a bitter principle of Rhamnus prinoides and other constituents of the leaves. Bull. Chem. Soc. Ethiop. 9 (1995) 107-114
2. Ali B.H., Al-Qarawi A., and Mousa H.M. Effect of grapefruit juice and cimetidine on the concentration of chloroquine in plasma of chicken. Ind. J. Pharmacol. 33 (2001) 289-290
3. Ali B.H., Al-Qarawi A., and Mousa H.M. Effect of grapefruit juice on plasma chloroquine kinetics in mice. Clin. Exp. Pharmacol. Physiol. 29 (2002) 704-706
4. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
5. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
6. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
7. Augustijns P.F. Uptake and transport characteristics of chloroquine in an in-vitro cell culture system of the intestinal mucosa, Caco-2. J. Pharm. Pharmacol. 48 (1996) 277-280
8. Ayrton A., and Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31 (2001) 469-497
9. Butterweck V., Derendorf H., Gaus W., Nahrstedt A., Schulz V., and Unger M. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate?. Planta Med. 70 (2004) 784-791
10. Buxbaum E. Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1. Eur. J. Biochem. 265 (1999) 64-70
11. Castro A.F., and Altenberg G.A. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein*1. Biochem. Pharmacol. 53 (1997) 89-93
12. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.-M., Barron D., and Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. PNAS 95 (1998) 9831-9836
13. Dahan A., and Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur. J. Clin. Nutr. 58 (2004) 1-9
14. Deferme S., Mols R., Van Driessche W., and Augustijns P. Apricot extract inhibits the P-gp-mediated efflux of talinolol. J. Pharm. Sci. 91 (2002) 2539-2548
15. Drescher S., Glaeser H., Murdter T., Hitzl M., Eichelbaum M., and Fromm M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73 (2003) 223-231
16. Dresser G.K., and Bailey D.G. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur. J. Clin. Invest. 33 (2003) 10-16
17. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
18. Fairlamb A.H. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 19 (2003) 488-494
19. Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 267 (2000) 277-294
20. Foley M., and Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79 (1998) 55-87
21. Gao J., Murase O., Schowen R.L., Aubé J., and Borchardt R.T. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. 18 (2001) 171-176
22. Giao P.T., and de Vries P.J. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40 (2001) 343-373
23. Grammate T., and Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66 (1999) 239-245
24. Gustafsson L.L., Walker O.A., lvan G., Beermann B., Estevez F., Gleisner L., Lindstrom B., and Sjoqvist F. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15 (1983) 471-479
25. Hager W.D., Fenster P., Mayersohn M., Perrier D., Graves P., Marcus F.I., and Goldman S. Digoxin-quinidine interaction pharmacokinetic evaluation. N. Engl. J. Med. 300 (1979) 1238-1241
26. Harris R.Z., Jang G.R., and Tsunoda S. Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. 42 (2003) 1071-1088
27. Hazra B., Sur P., Roy D.K., Sur B., and Banerjee A. Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice. Planta Med. 50 (1984) 295-297
28. Hunter J., and Hirst B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 225 (1997) 129-157
29. Karbwang J., Davis T.M.E., Looareesuwan S., Molunto P., Bunnag D., and White N.J. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br. J. Clin. Pharmacol. 35 (1993) 265-271
30. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. Jama 287 (2002) 337-344
31. Klepser T.B., Doucette W.R., Horton M.R., Buys L.M., Ernst M.E., Ford J.K., Hoehns J.D., Kautzman H.A., Logemann C.D., Swegle J.M., Ritho M., and Klepser M.E. Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20 (2000) 83-87
32. Kunta J.R., and Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 5 (2004) 109-124
33. Laurent F., Saivin S., Chretien P., Magnaval J.F., Peyron F., Sqalli A., Tufenkji A.E., Coulais Y., Baba H., Campistron G., Regis H., Ambroise-Thomas P., Bryskier A., and Houin G. Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. Arzneimittelforschung 43 (1993) 612-616
34. Liu Y., and Hu M. Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perused rat intestinal model. Drug Metab. Dispos. 30 (2002) 370-377
35. Loo T.W., and Clarke D.M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?. Biochem. Biophys. Res. Commun. 329 (2005) 419-422
36. Mahmoud B.M., Ali H.M., Homeida M.M.A., and Bennet J.L. Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. J. Antimicrob. Chemother. 33 (1994) 1005-1009
37. Masimirembwa C.M., Naik Y.S., and Hasler J.A. The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. Biopharm. Drug Dispos. 15 (1994) 33-43
38. Mueller O., Razum O., Traore C., and Kouyate B. Community effectiveness of chloroquine and traditional remedies in the treatment of young children with falciparum malaria in rural Burkina Faso. Malar. J. 3 (2004) 36
39. Nare B., Liu Z., Prichard R.K., and Georges E. Benzimidazoles, potent anti-mitotic drugs: substrates for the P-glycoprotein transporter in multidrug-resistant cells. Biochem. Pharmacol. 48 (1994) 2215-2222
40. Neuhoff S., Ungell A.L., Zamora I., and Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20 (2003) 1141-1148
41. Pereira P.C.M. Interaction between infection, nutrition and immunity in tropical medicine. J. Venom. Anim. Toxins Incl. Trop. Dis. 9 (2003) 163-173
42. Ray S., Hazra B., Mittra B., Das A., and Majumder H.K. Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol. Pharmacol. 54 (1998) 994-999
43. Sadeque A.J., Wandel C., He H., Shah S., and Wood A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68 (2000) 231-237
44. Scala S., Akhmed N., Rao U.S., Paull K., Lan L.-B., Dickstein B., Lee J.-S., Elgemeie G.H., Stein W.D., and Bates S.E. P-glycoprotein substrated and antagonists cluster into two distinct groups. Mol. Pharmacol. 51 (1997) 1024-1033
45. Scalbert A., and Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 130 (2000) 2073S-2085S
46. Scambia G., Ranelletti F.O., Panici P.B., De Vincenzo R., Bonanno G., Ferrandina G., Piantelli M., Bussa S., Rumi C., Cianfriglia M., et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 34 (1994) 459-464
47. Seithel A., Karlsson J., Hilgendorf C., Björquist A., and Ungell A.L. Variability in mRNA_expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28 (2006) 291-299
48. Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
49. Ungell A.L., and Karlsson J. Cell cultures in drug discovery: an industrial perspective. In: van de waterbeemd H., Lennernäs H., and Artursson P. (Eds). Drug Bioavailability; Estimation of Solubility, Permeability, Absorption and Bioavailability (2003), Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim 90-131
50. Walgren R.A., Walle U.K., and Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem. Pharmacol. 55 (1998) 1721-1727
51. Walker O., Salako L.A., Alvan G., Ericsson O., and Sjoqvist F. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br. J. Clin. Pharmacol. 23 (1987) 295-301
52. Wang Y.H., Chao P.D., Hsiu S.L., Wen K.C., and Hou Y.C. Lethal quercetin-digoxin interaction in pigs. Life Sci. 74 (2004) 1191-1197
53. Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., Oertel R., Terhaag B., Kroemer H.K., and Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68 (2000) 6-12
54. Winstanley P., Edwards G., Orme M., and Breckenridge A. The disposition of amodiaquine in man after oral administration. Br. J. Clin. Pharmacol. 23 (1987) 1-7
55. Yamano K., Yamamoto K., Kotaki H., Takedomi S., Matsuo H., Sawada Y., and Iga T. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J. Pharmacol. Exp. Ther. 292 (2000) 1118-1126